The Severe Acute Respiratory Syndrome, caused by a novel coronavlrus (SARS-CoV), resulted in substantial morbidity and mortality in 2002-2003. With the lack of recurrence of SARS, research efforts to understand pathogenesis and develop an effective vaccine have largely halted. However, coronaviruses similar to SARS-CoV have been identified in bats and other animal populations in China, making recurrence of SARS a possibility. Thus, we believe that efforts need to continue to understand pathogenesis and to develop vaccines and anti-viral therapies. In this PPG, several investigators with extensive experience in the pathogenesis, molecular biology and immunology of coronavirus infections will work together to better understand the interaction of SARS-CoV with the host respiratory tract and to develop novel approaches to preventing and treating SARS-CoV infections. These objectives will be investigated in the following projects. Project 1 will investigate severe disease in young BALB/c and aged BALB/c and C57BL/6 mice infected with mouse-adapted SARS-CoV and in SARS-CoV-infected mice that are transgenic for the human cellular receptor (angiotensin converting enzyme 2, hACE2). Project 2 will focus on the role of ACE2 signaling in pathogenesis. This project will also investigate the role of ACE2 by comparing cells and mice infected with SARS-CoV and HCoV-NL63, a common cold virus that also uses ACE2 to enter cells but does not cause severe disease. Project 3 will investigate the mechanism of action of two novel anti-virus therapies (rhesus theta defensin and griffithsin) and will investigate the role of ACE2 shedding in pathogenesis. Project 4 will develop and evaluate live attenuated SARS-CoV vaccines, based on the observation that virus deleted in the small envelope protein is viable, immunogenic and safe. All of the projects will use the Virology/Animal Models Core, which will engineer and propagate recombinant SARSCoV and will also analyze infected mice. Using the Core for these purposes will ensure reproducibility and ensure most effective use of our resources. These projects are all interrelated, will provide new information about SAR-CoV pathogenesis and will take advantage of the unique skills and expertise of the project directors.

Public Health Relevance

The overall goal of this Program Project grant is to understand the pathogenesis of severe respiratory infections caused by the SARS-coronavirus and to develop and evaluate novel vaccines and anti-viral therapies that might be useful in future outbreaks.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060699-07
Application #
8304203
Study Section
Special Emphasis Panel (ZAI1-EC-M (S1))
Program Officer
Stemmy, Erik J
Project Start
2004-08-01
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
7
Fiscal Year
2012
Total Cost
$1,595,795
Indirect Cost
$371,631
Name
University of Iowa
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Park, Jung-Eun; Li, Kun; Barlan, Arlene et al. (2016) Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A 113:12262-12267
Zuñiga, Sonia; Pascual-Iglesias, Alejandro; Sanchez, Carlos M et al. (2016) Virulence factors in porcine coronaviruses and vaccine design. Virus Res 226:142-151
Perlman, Stanley; Vijay, Rahul (2016) Middle East respiratory syndrome vaccines. Int J Infect Dis 47:23-8
Meyerholz, David K; Lambertz, Allyn M; McCray Jr, Paul B (2016) Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 186:78-86
Vijay, Rahul; Perlman, Stanley (2016) Middle East respiratory syndrome and severe acute respiratory syndrome. Curr Opin Virol 16:70-6
Fehr, Anthony R; Channappanavar, Rudragouda; Jankevicius, Gytis et al. (2016) The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. MBio 7:
Zhang, Naru; Channappanavar, Rudragouda; Ma, Cuiqing et al. (2016) Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 13:180-90
Luke, Thomas; Wu, Hua; Zhao, Jincun et al. (2016) Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8:326ra21
Channappanavar, Rudragouda; Fehr, Anthony R; Vijay, Rahul et al. (2016) Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19:181-93
Alshukairi, Abeer N; Khalid, Imran; Ahmed, Waleed A et al. (2016) Antibody Response and Disease Severity in Healthcare Worker MERS Survivors. Emerg Infect Dis 22:

Showing the most recent 10 out of 80 publications